The following listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Presently Amended) A compound of Formula I !:

$$\begin{array}{c|c}
H & R^1 \\
\hline
N & N \\
\hline
N & N \\
R^2
\end{array}$$

wherein,

R¹ is H,

alkyl having 1 to 5 carbon atoms, which is <u>unsubstituted</u> unsustituted or substituted one or more times by halogen, hydroxy, or combinations thereof, and wherein a -CH₂- group can be optionally replaced by -O-, -S-, or -NH-,

cycloalkyl having 3 to 6 carbon atoms, or

cycloalkylalkyl having 4 to 7 C atoms; and

R² is alkyl having 1 to 12 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, cyano or combinations thereof, wherein one or more -CH₂- groups is each independently optionally replaced by -O-, -S-, or -NH-, and wherein optionally one or more -CH₂CH₂- groups is replaced in each case by -CH=CH- or -C≡C-,

alkyl ether having 3 to 12 carbon atoms,

cycloalkyl having 3 to 12 carbon atoms, which is unsubstituted or substituted one or more times by halogen, C_{1-4} alkyl, halogenated C_{1-4} alkyl, C_{1-4} alkoxy, cyano or combinations thereof.

cycloalkylalkyl having 4 to 12 C atoms, which is unsubstituted or substituted one or more times by C_{1-4} alkyl, halogenated C_{1-4} alkyl, C_{1-4} alkoxy, cyano, halogen, or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, C_{1-4} alkylamino, di- C_{1-4} -alkylamino, C_{1-4} -hydroxyalkyl, C_{1-4} -hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, C_{2-4} -acyl, C_{2-4} -alkoxycarbonyl, C_{1-4} -alkylsulphinyl, C_{1-4} -alkylsulphonyl, phenoxy, or combinations thereof.

arylalkyl having 7 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, C_{1-4} alkylamino, di- C_{1-4} -alkylamino, C_{1-4} -hydroxyalkyl, C_{1-4} -hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, C_{2-4} -acyl, C_{2-4} -alkoxycarbonyl, C_{1-4} -alkylthio, C_{1-4} -alkylsulphinyl, C_{1-4} -alkylsulphonyl, phenoxy, or combinations thereof,

heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, aryl, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, C_{1-4} -alkylamino, di- C_{1-4} -alkylamino, carboxy, alkoxycarbonyl, hydroxamic acid, carboxamide, C_{1-4} -alkylthio, C_{1-4} -alkylsulphinyl, C_{1-4} -alkylsulphonyl, or combinations thereof,

heteroarylalkyl wherein the heteroaryl portion has 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and the alkyl portion has 1 to 3 carbon atoms, the heteroaryl portion is unsubstituted or is substituted one or more times in by halogen, aryl, $C_{1.4}$ alkyl, halogenated $C_{1.4}$ alkyl, hydroxy, $C_{1.4}$ -alkoxy, halogenated $C_{1.4}$ alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, $C_{1.4}$ -alkylamino, di- $C_{1.4}$ -alkylamino, carboxy, alkoxycarbonyl, hydroxamic acid, carboxamide, $C_{1.4}$ -alkylthio, $C_{1.4}$ -alkylsulphinyl, $C_{1.4}$ -alkylsulphonyl, or combinations thereof,

heterocycle having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or is substituted one or more times in the by heterocycle-alkyl wherein the heterocycle portion has 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and the alkyl portion has 1 to 3 carbon atoms, the heterocycle portion is nonarmoatic and is unsubstituted or is substituted one or more times in the by halogen, aryl, C₁₋₄ alkyl, halogenated C₁₋₄ alkyl, hydroxy, C₁₋₄-alkoxy, halogenated C₁₋₄ alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, C₁₋₄-alkylamino, di-C₁₋₄-alkylamino, carboxy, alkoxycarbonyl, or combinations thereof, or

carbocycle which is nonaromatic, monocyclic or bicyclic, group having 5 to 14 carbon atoms, which is unsubstituted or is substituted one or more times in the by halogen, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, C_{1-4} alkylamino, di- C_{1-4} -alkylamino, C_{1-4} -hydroxyalkyl, C_{1-4} -hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, C_{2-4} -acyl, C_{2-4} -alkoxycarbonyl, C_{1-4} -alkylthio, C_{1-4} -alkylsulphinyl, C_{1-4} -alkylsulphonyl, phenoxy, or combinations thereof;halogen, aryl, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, C_{1-4} -alkylamino, di- C_{1-4} -alkylamino, carboxy, alkoxycarbonyl, or combinations thereof; and

with the provisos that:

- (a) when R¹ is methyl, then R² is not arylalkyl, heteroarylalkyl, 2-(1,2,3,4-tetrahydro)quinolinyl-methyl, methyl or 2-butyl;
- (b) when R¹ is cyclopropyl, R² is not 4-methylbenzyl;
- (c) when R¹ is ethyl, then R² is not ethyl, 3-aminobenzyl, 2-thienylmethyl, 3-thienylmethyl, or 2-pyridylmethyl;
- (d) when R¹ is cyclopropyl, then R² is not cyclopropylmethyl;
- (e) when R¹ is H, then R² is not methyl, ethyl, benzyl, 4-methylbenzyl, or substituted tetrahydrofuranyl;
- (f) when R¹ is methoxyethyl, then R² is not benzyl, 3-dimethylaminobenzyl, or 3-thienylmethyl;
- (g) when R¹ is iso-butyl, then R² is not benzyl; and
- (h) when R¹ is n-butyl, then R² is not n-butyl.
- 2. (Original): A compound according to claim 1, wherein when R^1 is methyl, R^2 is not arylalkyl, heteroarylalkyl, 2-(1,2,3,4-tetrahydro)quinolinyl-methyl or C_{1-5} -alkyl.
 - 3. (Original): A compound according to claim 1, wherein R¹ is alkyl.
 - 4. (Original): A compound according to claim 1, wherein R¹ is cycloalkyl.
- 5. (Original): A compound according to claim 1, wherein R¹ is cycloalkylalkyl.
 - 6. (Original): A compound according to claim 1, wherein R² is alkyl.
 - 7. (Original): A compound according to claim 1, wherein R² is alkyl ether.
 - 8. (Original): A compound according to claim 1, wherein R² is cycloalkyl.

- 9. (Original): A compound according to claim 1, wherein R² is aryl.
- 10. (Original): A compound according to claim 1, wherein R² is arylalkyl.
- 11. (Original): A compound according to claim 1, wherein R² is heteroaryl.
- 12. (Original): A compound according to claim 1, wherein R² is heteroarylalkyl.
 - 13. (Original): A compound according to claim 1, wherein R² heterocycle.
- 14. (Original): A compound according to claim 1, wherein R² heterocyclealkyl.
 - 15. (Original): A compound according to claim 1, wherein R²carbocycle.
- 16. (Original): A compound according to claim 1, wherein R¹ is alkyl, substituted alkyl, cycloalkyl or cycloalkylalkyl.
- 17. (Original): A compound according to claim 6, wherein R¹ is alkyl, cycloalkyl or cycloalkylalkyl.
- 18. (Original): A compound according to claim 7, wherein R¹ is alkyl, cycloalkyl or cycloalkylalkyl.
- 19. (Original): A compound according to claim 8, wherein R¹ is alkyl, cycloalkyl or cycloalkylalkyl.
- 20. (Original): A compound according to claim 9, wherein R¹ is alkyl, cycloalkyl or cycloalkylalkyl.

ţ,

21. (Original): A compound according to claim 10, wherein R¹ is alkyl, cycloalkyl or cycloalkylalkyl.

4.

BI

- 22. (Original): A compound according to claim 11, wherein R¹ is alkyl, cycloalkyl or cycloalkylalkyl.
- 23. (Original): A compound according to claim 12, wherein R¹ is alkyl, cycloalkyl or cycloalkylalkyl.
- 24. (Original): A compound according to claim 13, wherein R¹ is alkyl, cycloalkyl or cycloalkylalkyl.
- 25. (Original): A compound according to claim 14, wherein R¹ is alkyl, cycloalkyl or cycloalkylalkyl.
- 26. (Original): A compound according to claim 15, wherein R¹ is alkyl, cycloalkyl or cycloalkylalkyl.
- 27. (Original): A compound according to claim 1, wherein R¹ is methyl, ethyl, isopropyl, 2-hydroxyethyl, cyclopropyl, cyclopentyl, or cyclopropylmethyl.
- 28. (Original): A compound according to claim 1, wherein R¹ is methyl, ethyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
- 29. (Original): A compound according to claim 1, wherein R¹ is methyl, ethyl or cyclopropyl.
- 30. (Original): A compound according to claim 1, wherein R² is alkyl, arylalkyl, cycloalkyl, aryl, heteroaryl, heteroarylalkyl, or alkyl ether.

- 31. (Original): A compound according to claim 1, wherein R² is ethyl, isopropyl, butyl, tert-butyl, cyclopentyl, cyclohexyl, cycloheptyl, or arylalkyl which is unsubstituted or substituted one or more times by F, Cl, CN, CF₃, CH₃, C₂H₅, isopropyl, OCH₃, methylenedioxy, ethylenedioxy or combinations thereof.
- 32. (Original): A compound according to claim 1, wherein R² is substituted or unsubstituted benzyl, phenethyl or phenpropyl.
 - 33. (Presently Amended): A compound of formula H II

wherein

R1' is methyl, ethyl, or cyclopropyl; and

R^{2'} is cycloalkyl having 3 to 12 carbon atoms, which is unsubstituted or substituted one or more times by halogen, C₁₋₄ alkyl, halogenated C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, C_{1-4} alkylamino, di- C_{1-4} -alkylamino, C_{1-4} -hydroxyalkyl, C_{1-4} -hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, C_{2-4} -acyl, C_{2-4} -alkoxycarbonyl, C_{1-4} -alkylsulphinyl, C_{1-4} -alkylsulphonyl, phenoxy, or combinations thereof,

heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, aryl, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, C_{1-4} -alkylamino, di- C_{1-4} -alkylamino, carboxy, alkoxycarbonyl, hydroxamic acid, carboxamide, C_{1-4} -alkylthio, C_{1-4} -alkylsulphinyl, C_{1-4} -alkylsulphonyl, or combinations thereof,

101

heterocycle having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or is substituted one or more times in the by halogen, aryl, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, C_{1-4} -alkylamino, di- C_{1-4} -alkylamino, carboxy, alkoxycarbonyl, or combinations thereof (e.g., piperidinyl, imidazolinyl, imidazolidinyl, pyrrolinyl, pyrrolidinyl, morpholinyl, piperazinyl, and indolinyl), or

carbocycle which is nonaromatic, monocyclic or bicyclic, group having 5 to 14 carbon atoms, which is unsubstituted or is substituted one or more times in the by halogen, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, C_{1-4} alkylamino, di- C_{1-4} -alkylamino, C_{1-4} -hydroxyalkyl, C_{1-4} -hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, C_{2-4} -acyl, C_{2-4} -alkoxycarbonyl, C_{1-4} -alkylthio, C_{1-4} -alkylsulphinyl, C_{1-4} -alkylsulphonyl, phenoxy, or combinations thereof; and

pharmaceutically acceptable salts thereof.

34. (Presently Amended): A compound of Formula ## !!!:

wherein

wherei

R¹" is methyl, ethyl, or cyclopropyl; and

R²" is phenyl,

phenyl which is substituted one or more times by halogen, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, C_{1-4} -alkylamino, di- C_{1-4} -alkylamino, C_{1-4} -hydroxyalkyl, C_{1-4} -hydroxyalkoxy, carboxy, cyano, C_{2-4} -acyl, C_{2-4} -alkoxycarbonyl, C_{1-4} -alkylthio, C_{1-4} -alkylsulphinyl, C_{1-4} -alkylsulphonyl, phenoxy, or combinations thereof, or

heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, substituted heteroaryl having 5 to 10 ring atoms, in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, aryl, C₁₋₄-alkyl, C₁₋₄-alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, C₁₋₄-alkylamino, di-C₁₋₄-alkylamino or combinations thereof,

or when R¹ is methyl or cyclopropyl R² can also be cycloalkyl having 3 to 12 carbon atoms; and

pharmaceutically acceptable salts thereof.

- 35. (Original): A compound according to claim 1, wherein said compound selected from:
- 6-Cyclopropylamino-9-(2-fluorobenzyl)-2-trifluoromethylpurine
- 6-Ethylamino-9-(2-fluorobenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-fluorobenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2, 6-difluorobenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2, 3-difluorobenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-propyl 2-trifluoromethylpurine
- 6-Cyclopropylamino-9-cyclopentyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3, 4-dimethoxybenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3,4-methylenedioxybenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-thiophenemethyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2-methylphenethyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-cycloheptyl-2-trifluoromethylpurine
- 6-Methylamino-9-cyclopentyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-cyclohexyl-2-trifluoromethylpurine
- 6-Methylamino-9-cycloheptyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-cyclopentylmethyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-phenyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2-fluorophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-cyclobutyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2-norboranane)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(1-indanyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-fluorophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-chlorophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-thienyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-cyclopentyloxy-4-methoxybenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3, 4-dimethoxyphenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2, 6-dichloro-4-pyridylmethyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-methoxybenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-methoxyphenyl)-2-trifluoromethylpurine

- 6-Cyclopropylamino-9-(3-nitrophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2-methoxyphenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-cyanophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2, 4-dimethoxyphenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-nitrobenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(6-methoxy-3-pyridyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-pyridyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-pyridyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-dimethylaminophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-aminophenyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(2, 4-dimethoxy-5-pyrimidyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(2-methoxyphenyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(4-methoxyphenyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(3-acetylphenyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(3-methoxyphenyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(3-nitrophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-furanyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-ethoxyphenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2-ethoxyphenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3, 4-methylenedioxyphenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-ethoxyphenyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(3,4-dimethoxyphenyl)-2-trifluoromethylpurine; and

pharmaceutically acceptable salts thereof.

- 36. (Original): A compound according to claim 34, wherein said compound selected from:
- 6-Cyclopropylamino-9-(2,3-difluorobenzyl)-2-trifluoromethylpurine

- 6-Cyclopropylamino-9-cyclopentyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3,4-dimethoxybenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-cycloheptyl-2-trifluoromethylpurine
- 6-Methylamino-9-cyclopentyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-cyclohexyl-2-trifluoromethylpurine
- 6-Methylamino-9-cycloheptyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-phenyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2-fluorophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-cyclobutyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2-norboranane)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-fluorophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-chlorophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-thienyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3, 4-dimethoxyphenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2, 6-dichloro-4-pyridylmethyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-methoxybenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-methoxyphenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-methoxyphenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-nitrophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2-methoxyphenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-cyanophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-nitrobenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-pyridyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(2, 4-dimethoxy-5-pyrimidyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(4-methoxyphenyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(3-acetylphenyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(3-methoxyphenyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(3-nitrophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-ethoxyphenyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(3,4-dimethoxyphenyl)-2-trifluoromethylpurine; and



pharmaceutically acceptable salts thereof.

37. (Cancelled):

- 38. (Presently Amended): A method according to claim <u>54</u> 37, wherein said compound is administered in an amount of 0.01-100 mg/kg of body weight/day.
- 39. (Presently Amended): A method according to claim <u>54</u> 37, wherein said patient is a human.
- 40. (Presently Amended): A method according to claim <u>54</u> 37, wherein said compound selected from:
- 6-Cyclopropylamino-9-(2-fluorobenzyl)-2-trifluoromethylpurine;
- 6-Ethylamino-9-(2-fluorobenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-fluorobenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2, 6-difluorobenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2, 3-difluorobenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-propyl 2-trifluoromethylpurine
- 6-Cyclopropylamino-9-cyclopentyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3, 4-dimethoxybenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3,4-methylenedioxybenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-thiophenemethyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2-methylphenethyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-cyclopropylmethyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-cycloheptyl-2-trifluoromethylpurine
- 6-Methylamino-9-cyclopentyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-cyclohexyl-2-trifluoromethylpurine
- 6-Methylamino-9-cycloheptyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-cyclopentylmethyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-phenyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2-fluorophenyl)-2-trifluoromethylpurine



6-Cyclopropylamino-9-(2-norboranane)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(1-indanyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(4-fluorophenyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(4-chlorophenyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(4-tolyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(3-thienyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(3-cyclopentyloxy-4-methoxybenzyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(3, 4-dimethoxyphenyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(2, 6-dichloro-4-pyridylmethyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(4-methoxybenzyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(3-methoxyphenyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(4-methoxyphenyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(3-nitrophenyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(2-methoxyphenyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(3-cyanophenyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(2, 4-dimethoxyphenyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(3-nitrobenzyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(6-methoxy-3-pyridyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(4-pyridyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(3-pyridyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(4-dimethylaminophenyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(3-aminophenyl)-2-trifluoromethylpurine

6-Methylamino-9-(2, 4-dimethoxy-5-pyrimidyl)-2-trifluoromethylpurine

6-Methylamino-9-(2-methoxyphenyl)-2-trifluoromethylpurine

6-Methylamino-9-(4-methoxyphenyl)-2-trifluoromethylpurine

6-Methylamino-9-(3-acetylphenyl)-2-trifluoromethylpurine

6-Methylamino-9-(3-methoxyphenyl)-2-trifluoromethylpurine

6-Methylamino-9-(3-nitrophenyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(3-furanyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(4-ethoxyphenyl)-2-trifluoromethylpurine

- $\hbox{6-Cyclopropylamino-9-(2-ethoxyphenyl)-2-trifluoromethyl purine}$
- 6-Cyclopropylamino-9-(3, 4-methylenedioxyphenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-ethoxyphenyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(3,4-dimethoxyphenyl)-2-trifluoromethylpurine
- 6 Methylamino 9 (3,4-dimethoxyphenyl) 2 trifluoromethylpurinep; and pharmaceutically acceptable salts thereof.
- 41. (Original): A method according to claim 40, wherein said patient is a human.
- 42. (Original): A method according to claim 41, wherein said compound is administered in an amount of 0.01-100 mg/kg of body weight/day.
 - 43. (Cancelled):
 - 44. (Cancelled):
 - 45. (Cancelled):
- 46. (Presently Amended): A method according to claim <u>57</u> 45, wherein said patient is a human.
- 47. (Original): A method according to claim 46, wherein said patient is suffering from memory impairment.
- 48 49. (Presently Amended): A method according to claim 57 45, wherein said compound is administered in an amount of 0.01-100 mg/kg of body weight/day.
 - 49. (Original claim 50) (Cancelled):
 - 50 51. (Presently Amended): A method according to claim 57 45, wherein said

compound selected from:

- 6-Cyclopropylamino-9-(2-fluorobenzyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(2-fluorobenzyl)-2-trifluoromethylpurine
- 6-Ethylamino-9-(2-fluorobenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-fluorobenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2, 6-difluorobenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2, 3-difluorobenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-propyl 2-trifluoromethylpurine
- 6-Cyclopropylamino-9-cyclopentyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3, 4-dimethoxybenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3,4-methylenedioxybenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-thiophenemethyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2-methylphenethyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-cyclopropylmethyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-cycloheptyl-2-trifluoromethylpurine
- 6-Methylamino-9-cyclopentyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-cyclohexyl-2-trifluoromethylpurine
- 6-Methylamino-9-cycloheptyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-cyclopentylmethyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-phenyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2-fluorophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-cyclobutyl-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2-norboranane)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(1-indanyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-fluorophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-chlorophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-tolyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-thienyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-cyclopentyloxy-4-methoxybenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3, 4-dimethoxyphenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2, 6-dichloro-4-pyridylmethyl)-2-trifluoromethylpurine



- B

- $\hbox{6-Cyclopropylamino-9-(4-methoxybenzyl)-2-trifluoromethyl purine} \\$
- 6-Cyclopropylamino-9-(3-methoxyphenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-methoxyphenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-nitrophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2-methoxyphenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-cyanophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2, 4-dimethoxyphenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-nitrobenzyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(6-methoxy-3-pyridyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-pyridyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-pyridyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-dimethylaminophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-aminophenyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(2, 4-dimethoxy-5-pyrimidyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(2-methoxyphenyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(4-methoxyphenyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(3-acetylphenyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(3-methoxyphenyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(3-nitrophenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-furanyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(4-ethoxyphenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(2-ethoxyphenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3, 4-methylenedioxyphenyl)-2-trifluoromethylpurine
- 6-Cyclopropylamino-9-(3-ethoxyphenyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(3,4-dimethoxyphenyl)-2-trifluoromethylpurine
- 6-Methylamino-9-(3,4-dimethoxyphenyl)-2-trifluoromethylpurinep; and pharmaceutically acceptable salts thereof.
- <u>51</u> 52. (Presently Amended): A method according to claim <u>50</u> 51, wherein said patient is a human.

- 52. (Original Claim 53) (Cancelled):
- 53. (Original Claim 54) (Cancelled):

 $\underline{54}$ 56. (Presently Amended): A method for treating a patient having a disease involving decreased cAMP levels comprising administering to said patient an effective amount of a compound according to formula $I^e \underline{I^c}$:

Bl

wherein,

R^{1c} is H,

alkyl having 1 to 5 carbon atoms, which is <u>unsubstituted</u> unsustituted or substituted one or more times by halogen, hydroxy, or combinations thereof, and wherein a -CH₂- group can be optionally replaced by -O-, -S-, or -NH-,

cycloalkyl having 3 to 6 carbon atoms, or

cycloalkylalkyl having 4 to 7 C atoms;

R^{2c} is alkyl having 1 to 12 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, cyano or combinations thereof, wherein one or more -CH₂- groups is each independently optionally replaced by -O-, -S-, or -

NH-, and wherein optionally one or more -CH₂CH₂- groups is replaced in each case by -CH=CH- or -C \equiv C-,

alkyl ether having 3 to 12 carbon atoms,

cycloalkyl having 3 to 12 carbon atoms, which is unsubstituted or substituted one or more times by halogen, C_{1-4} alkyl, halogenated C_{1-4} alkyl, C_{1-4} alkoxy, cyano or combinations thereof,

cycloalkylalkyl having 4 to 12 C atoms, which is unsubstituted or substituted one or more times by C_{1-4} alkyl, halogenated C_{1-4} alkyl, C_{1-4} alkoxy, cyano, halogen, or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, C_{1-4} alkylamino, di- C_{1-4} -alkylamino, C_{1-4} -hydroxyalkyl, C_{1-4} -hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, C_{2-4} -acyl, C_{2-4} -alkoxycarbonyl, C_{1-4} -alkylsulphinyl, C_{1-4} -alkylsulphonyl, phenoxy, or combinations thereof,

arylalkyl having 7 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, C_{1-4} alkylamino, di- C_{1-4} -alkylamino, C_{1-4} -hydroxyalkyl, C_{1-4} -hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, C_{2-4} -acyl, C_{2-4} -alkoxycarbonyl, C_{1-4} -alkylthio, C_{1-4} -alkylsulphinyl, C_{1-4} -alkylsulphonyl, phenoxy, or combinations thereof,

heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom,

which is unsubstituted or substituted one or more times by halogen, aryl, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, C_{1-4} -alkylamino, di- C_{1-4} -alkylamino, carboxy, alkoxycarbonyl, hydroxamic acid, carboxamide, C_{1-4} -alkylthio, C_{1-4} -alkylsulphinyl, C_{1-4} -alkylsulphonyl, or combinations thereof,

heteroarylalkyl wherein the heteroaryl portion has 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and the alkyl portion has 1 to 3 carbon atoms, the heteroaryl portion is unsubstituted or is substituted one or more times in by halogen, aryl, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, C_{1-4} -alkylamino, di- C_{1-4} -alkylamino, carboxy, alkoxycarbonyl, hydroxamic acid, carboxamide, C_{1-4} -alkylthio, C_{1-4} -alkylsulphinyl, C_{1-4} -alkylsulphonyl, or combinations thereof,

heterocycle having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or is substituted one or more times in the by halogen, aryl, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, C_{1-4} -alkylamino, di- C_{1-4} -alkylamino, carboxy, alkoxycarbonyl, or combinations thereof,

heterocycle-alkyl wherein the heterocycle portion has 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and the alkyl portion has 1 to 3 carbon atoms, the heterocycle portion is nonarmoatic and is unsubstituted or is substituted one or more times in the by halogen, aryl, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, C_{1-4} -alkylamino, di- C_{1-4} -alkylamino, carboxy, alkoxycarbonyl, or combinations thereof, or

p

carbocycle which is nonaromatic, monocyclic or bicyclic, group having 5 to 14 carbon atoms, which is unsubstituted or is substituted one or more times in the by halogen, C₁₋₄ alkyl, halogenated C₁₋₄ alkyl, hydroxy, C₁₋₄-alkoxy, halogenated C₁₋₄ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, C₁₋₄ alkylamino, di-C₁₋₄-alkylamino, C₁₋₄-hydroxyalkyl, C₁₋₄-hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, C₂₋₄-acyl, C₂₋₄-alkoxycarbonyl, C₁₋₄-alkylthio, C₁₋₄-alkylsulphonyl, phenoxy, or combinations thereof; and

pharmaceutically acceptable salts thereof,

with the proviso that said compound is not 6-methylamino-9-(2-fluorobenzyl)-2-trifluoromethylpurine.

55 57. (Presently Amended): A method according to claim 54 56, wherein when R^{1c} is methyl, then R^{2c} is not arylalkyl, methyl or 2-butyl, and when R^{1c} is H, then R^{2c} is not benzyl.

56 58. (Presently Amended): A method according to claim 54 56, wherein:

- (a) when R^{1c} is methyl, then R^{2c} is not arylalkyl, heteroarylalkyl, 2-(1,2,3,4-tetrahydro)quinolinyl-methyl, methyl or 2-butyl;
- (b) when R^{1c} is cyclopropyl, R^{2c} is not 4-methylbenzyl;
- (c) when R^{1c} is ethyl, then R^{2c} is not ethyl, 3-aminobenzyl, 2-thienylmethyl, 3-thienylmethyl, or 2-pyridylmethyl;
- (d) when R^{1c} is cyclopropyl, then R^{2c} is not cyclopropylmethyl;
- (e) when R^{1c} is H, then R^{2c} is not methyl, ethyl, benzyl, 4-methylbenzyl, or substituted tetrahydrofuranyl;
- (f) when R^{1c} is methoxyethyl, then R^{2c} is not benzyl, 3-dimethylaminobenzyl, or 3-thienylmethyl;
- (g) when R^{1c} is iso-butyl, then R^{2c} is not benzyl; and
- (h) when R^{1c} is n-butyl, then R^{2c} is not n-butyl.

 $\underline{57}$ 59. (Presently Amended): A method of inhibiting PDE4 enzyme activity in a patient comprising administering to said patient an effective amount of a compound according to formula $I^e \underline{I}^c$:

wherein,

R^{1c} is H,

alkyl having 1 to 5 carbon atoms, which is <u>unsubstituted</u> unsustituted or substituted one or more times by halogen, hydroxy, or combinations thereof, and wherein a -CH₂- group can be optionally replaced by -O-, -S-, or -NH-,

cycloalkyl having 3 to 6 carbon atoms, or

cycloalkylalkyl having 4 to 7 C atoms;

R^{2c} is alkyl having 1 to 12 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, cyano or combinations thereof, wherein one or more -CH₂- groups is each independently optionally replaced by -O-, -S-, or -NH-, and wherein optionally one or more -CH₂CH₂- groups is replaced in each case by -CH=CH- or -C≡C-₂

alkyl ether having 3 to 12 carbon atoms,

cycloalkyl having 3 to 12 carbon atoms, which is unsubstituted or substituted one or more times by halogen, C_{1-4} alkyl, halogenated C_{1-4} alkyl, C_{1-4} alkoxy, cyano or combinations thereof,

cycloalkylalkyl having 4 to 12 C atoms, which is unsubstituted or substituted one or more times by C_{1-4} alkyl, halogenated C_{1-4} alkyl, C_{1-4} alkoxy, cyano, halogen, or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, $C_{1\cdot4}$ alkyl, halogenated $C_{1\cdot4}$ alkyl, hydroxy, $C_{1\cdot4}$ -alkoxy, halogenated $C_{1\cdot4}$ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1\cdot4}$ alkylamino, di- $C_{1\cdot4}$ -alkylamino, $C_{1\cdot4}$ -hydroxyalkyl, $C_{1\cdot4}$ -hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, $C_{2\cdot4}$ -acyl, $C_{2\cdot4}$ -alkoxycarbonyl, $C_{1\cdot4}$ -alkylsulphinyl, $C_{1\cdot4}$ -alkylsulphonyl, phenoxy, or combinations thereof,

arylalkyl having 7 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, C_{1-4} alkylamino, di- C_{1-4} -alkylamino, C_{1-4} -hydroxyalkyl, C_{1-4} -hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, C_{2-4} -acyl, C_{2-4} -alkoxycarbonyl, C_{1-4} -alkylthio, C_{1-4} -alkylsulphinyl, C_{1-4} -alkylsulphonyl, phenoxy, or combinations thereof,

heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, aryl, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, C_{1-4} -alkylamino, di- C_{1-4} -alkylamino,

BI

carboxy, alkoxycarbonyl, hydroxamic acid, carboxamide, $C_{1.4}$ -alkylthio, $C_{1.4}$ -alkylsulphinyl, $C_{1.4}$ -alkylsulphonyl, or combinations thereof,

heteroarylalkyl wherein the heteroaryl portion has 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and the alkyl portion has 1 to 3 carbon atoms, the heteroaryl portion is unsubstituted or is substituted one or more times in by halogen, aryl, $C_{1.4}$ alkyl, halogenated $C_{1.4}$ alkyl, hydroxy, $C_{1.4}$ -alkoxy, halogenated $C_{1.4}$ alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, $C_{1.4}$ -alkylamino, di- $C_{1.4}$ -alkylamino, carboxy, alkoxycarbonyl, hydroxamic acid, carboxamide, $C_{1.4}$ -alkylthio, $C_{1.4}$ -alkylsulphinyl, $C_{1.4}$ -alkylsulphonyl, or combinations thereof,

heterocycle having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or is substituted one or more times in the by halogen, aryl, $C_{1.4}$ alkyl, halogenated $C_{1.4}$ alkyl, hydroxy, $C_{1.4}$ -alkoxy, halogenated $C_{1.4}$ alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, $C_{1.4}$ -alkylamino, di- $C_{1.4}$ -alkylamino, carboxy, alkoxycarbonyl, or combinations thereof,

heterocycle-alkyl wherein the heterocycle portion has 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and the alkyl portion has 1 to 3 carbon atoms, the heterocycle portion is nonarmoatic and is unsubstituted or is substituted one or more times in the by halogen, aryl, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, C_{1-4} -alkylamino, di- C_{1-4} -alkylamino, carboxy, alkoxycarbonyl, or combinations thereof,or

carbocycle which is nonaromatic, monocyclic or bicyclic, group having 5 to 14 carbon atoms, which is unsubstituted or is substituted one or more times in the by halogen, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, C_{1-4} alkylamino, di- C_{1-4} -

BI

alkylamino, C_{1-4} -hydroxyalkyl, C_{1-4} -hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, C_{2-4} -acyl, C_{2-4} -alkoxycarbonyl, C_{1-4} -alkylthio, C_{1-4} -alkylsulphinyl, C_{1-4} -alkylsulphonyl, phenoxy, or combinations thereof; and

pharmaceutically acceptable salts thereof,

with the proviso that said compound is not 6-methylamino-9-(2-fluorobenzyl)-2-trifluoromethylpurine.

 $\underline{58}$ 60. (Presently Amended): A method according to claim $\underline{57}$ 59, wherein when R^{1c} is methyl, then R^{2c} is not arylalkyl, methyl or 2-butyl, and when R^{1c} is H, then R^{2c} is not benzyl

- 59 61. (Presently Amended): A method according to claim 57 59, wherein:
- (a) when R^{1c} is methyl, then R^{2c} is not arylalkyl, heteroarylalkyl, 2-(1,2,3,4-tetrahydro)quinolinyl-methyl, methyl or 2-butyl;
- (b) when R^{1c} is cyclopropyl, R^{2c} is not 4-methylbenzyl;
- (c) when R^{1c} is ethyl, then R^{2c} is not ethyl, 3-aminobenzyl, 2-thienylmethyl, 3-thienylmethyl, or 2-pyridylmethyl;
- (d) when R^{1c} is cyclopropyl, then R^{2c} is not cyclopropylmethyl;
- (e) when R^{1c} is H, then R^{2c} is not methyl, ethyl, benzyl, 4-methylbenzyl, or substituted tetrahydrofuranyl;
- (f) when R^{1c} is methoxyethyl, then R^{2c} is not benzyl, 3-dimethylaminobenzyl, or 3-thienylmethyl;
- (g) when R^{1c} is iso-butyl, then R^{2c} is not benzyl; and
- (h) when R^{1c} is n-butyl, then R^{2c} is not n-butyl.
- <u>60</u> 62. (Presently Amended): A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

- $\underline{61}$ 63. (Presently Amended): A composition according to claim $\underline{60}$ 62, wherein said composition contains 0.1-50 mg of said compound.
 - 62. (Original Claim 64) (Cancelled):
 - 63. (Original Claim 65) (Cancelled):
 - 64. (Original Claim 66) (Cancelled):
 - 65. (Original Claim 67) (Cancelled):
 - 66. (Original Claim 68) (Cancelled):
 - 67. (Original Claim 64) (Cancelled):
- 68 70. (Presently Amended): A method of treating a patient suffering from an allergic or inflammatory disease, resulting from decreased cyclic AMP levels, elevated phosphodiesterase 4 levels, or both, comprising administering to said patient an effective amount of a compound according to formula I^e :

27

wherein,

R^{1c} is H,

alkyl having 1 to 5 carbon atoms, which is <u>unsubstituted</u> unsustituted or substituted one or more times by halogen, hydroxy, or combinations thereof, and wherein a -CH₂- group can be optionally replaced by -O-, -S-, or -NH-,

cycloalkyl having 3 to 6 carbon atoms, or

cycloalkylalkyl having 4 to 7 C atoms;

R^{2c} is alkyl having 1 to 12 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, cyano or combinations thereof, wherein one or more -CH₂- groups is each independently optionally replaced by -O-, -S-, or -NH-, and wherein optionally one or more -CH₂CH₂- groups is replaced in each case by -CH=CH- or -C≡C-,

alkyl ether having 3 to 12 carbon atoms,

cycloalkyl having 3 to 12 carbon atoms, which is unsubstituted or substituted one or more times by halogen, C_{1-4} alkyl, halogenated C_{1-4} alkyl, C_{1-4} alkoxy, cyano or combinations thereof,

cycloalkylalkyl having 4 to 12 C atoms, which is unsubstituted or substituted one or more times by C_{1-4} alkyl, halogenated C_{1-4} alkyl, C_{1-4} alkoxy, cyano, halogen, or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, C₁₋₄ alkyl, halogenated C₁₋₄ alkyl, hydroxy, C₁₋₄-alkoxy, halogenated C₁₋₄ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, C₁₋₄ alkylamino, di-C₁₋₄-alkylamino, C₁₋₄-hydroxyalkyl, C₁₋₄-hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, C₂₋₄-acyl, C₂₋₄-alkoxycarbonyl, C₁₋₄-

alkylthio, C_{1-4} -alkylsulphinyl, C_{1-4} -alkylsulphonyl, phenoxy, or combinations thereof,

arylalkyl having 7 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, C_{1-4} alkylamino, di- C_{1-4} -alkylamino, C_{1-4} -hydroxyalkyl, C_{1-4} -hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, C_{2-4} -acyl, C_{2-4} -alkoxycarbonyl, C_{1-4} -alkylsulphinyl, C_{1-4} -alkylsulphonyl, phenoxy, or combinations thereof,

heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, aryl, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, C_{1-4} -alkylamino, di- C_{1-4} -alkylamino, carboxy, alkoxycarbonyl, hydroxamic acid, carboxamide, C_{1-4} -alkylthio, C_{1-4} -alkylsulphinyl, C_{1-4} -alkylsulphonyl, or combinations thereof,

heteroarylalkyl wherein the heteroaryl portion has 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and the alkyl portion has 1 to 3 carbon atoms, the heteroaryl portion is unsubstituted or is substituted one or more times in by halogen, aryl, $C_{1.4}$ alkyl, halogenated $C_{1.4}$ alkyl, hydroxy, $C_{1.4}$ -alkoxy, halogenated $C_{1.4}$ alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, $C_{1.4}$ -alkylamino, di- $C_{1.4}$ -alkylamino, carboxy, alkoxycarbonyl, hydroxamic acid, carboxamide, $C_{1.4}$ -alkylthio, $C_{1.4}$ -alkylsulphinyl, $C_{1.4}$ -alkylsulphonyl, or combinations thereof,

heterocycle having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or is substituted one or more times in the by halogen, aryl, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, C_{1-4} -

BI

alkylamino, di-C₁₋₄-alkylamino, carboxy, alkoxycarbonyl, or combinations thereof,

heterocycle-alkyl wherein the heterocycle portion has 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and the alkyl portion has 1 to 3 carbon atoms, the heterocycle portion is nonarmoatic and is unsubstituted or is substituted one or more times in the by halogen, aryl, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, C_{1-4} -alkylamino, di- C_{1-4} -alkylamino, carboxy, alkoxycarbonyl, or combinations thereof, or

carbocycle which is nonaromatic, monocyclic or bicyclic, group having 5 to 14 carbon atoms, which is unsubstituted or is substituted one or more times in the by halogen, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, C_{1-4} alkylamino, di- C_{1-4} -alkylamino, C_{1-4} -hydroxyalkyl, C_{1-4} -hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, C_{2-4} -acyl, C_{2-4} -alkoxycarbonyl, C_{1-4} -alkylthio, C_{1-4} -alkylsulphinyl, C_{1-4} -alkylsulphonyl, phenoxy, or combinations thereof; and

pharmaceutically acceptable salts thereof,

with the proviso that said compound is not 6-methylamino-9-(2-fluorobenzyl)-2-trifluoromethylpurine.

 $\underline{69}$ 71. (Presently Amended): A method according to claim $\underline{68}$ 70, wherein when R^{1c} is methyl, then R^{2c} is not arylalkyl, methyl or 2-butyl, and when R^{1c} is H, then R^{2c} is not benzyl

70 72. (Presently Amended): A method according to claim 68 70, wherein: (a) when R^{1c} is methyl, then R^{2c} is not arylalkyl, heteroarylalkyl, 2-(1,2,3,4-

tetrahydro)quinolinyl-methyl, methyl or 2-butyl;

- (b) when R^{1c} is cyclopropyl, R^{2c} is not 4-methylbenzyl;
- (c) when R^{1c} is ethyl, then R^{2c} is not ethyl, 3-aminobenzyl, 2-thienylmethyl, 3-thienylmethyl, or 2-pyridylmethyl;
- (d) when R^{1c} is cyclopropyl, then R^{2c} is not cyclopropylmethyl;
- (e) when R^{1c} is H, then R^{2c} is not methyl, ethyl, benzyl, 4-methylbenzyl, or substituted tetrahydrofuranyl;
- (f) when R^{1c} is methoxyethyl, then R^{2c} is not benzyl, 3-dimethylaminobenzyl, or 3-thienylmethyl;
- (g) when R1c is iso-butyl, then R2c is not benzyl; and
- (h) when R^{1c} is n-butyl, then R^{2c} is not n-butyl.

7173. (Presently Amended): A process for preparing compounds of the formula VV

wherein

 R^1 is H,

alkyl having 1 to 5 carbon atoms, which is <u>unsubstituted</u> unsustituted or substituted one or more times by halogen, hydroxy, or combinations thereof, and wherein a -CH₂- group can be optionally replaced by -O-, -S-, or -NH-,

cycloalkyl having 3 to 6 carbon atoms, or

cycloalkylalkyl having 4 to 7 C atoms; and

is aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, C₁₋₄ alkyl, halogenated C₁₋₄ alkyl, hydroxy, C₁₋₄-alkoxy, halogenated C₁₋₄ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, C₁₋₄ alkylamino, di-C₁₋₄-alkylamino, C₁₋₄-hydroxyalkyl, C₁₋₄-hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, C₂₋₄-acyl, C₂₋₄-alkoxycarbonyl, C₁₋₄-alkylthio, C₁₋₄-alkylsulphinyl, C₁₋₄-alkylsulphonyl, phenoxy, or combinations thereof,

heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, aryl, C_{1-4} alkyl, halogenated C_{1-4} alkyl, hydroxy, C_{1-4} -alkoxy, halogenated C_{1-4} alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, C_{1-4} -alkylamino, di- C_{1-4} -alkylamino, carboxy, alkoxycarbonyl, hydroxamic acid, carboxamide, C_{1-4} -alkylthio, C_{1-4} -alkylsulphinyl, C_{1-4} -alkylsulphonyl, or combinations thereof,

said process comprising:

reacting 6-N-R¹-substituted adenine with an arylboronic acid or heteroarylboronic acid in the presence of trialkylamine wherein the alkyl <u>portions each</u> have 1 to 5 C atoms, e.g., triethylamine, as a base, a copper catalyst, and a polar aprotic solvent, for example THF and CH₂CN (particulary, CH₂CN)-at a temperature of at least 50°C, e.g., 50-60°C.

- $\underline{72}$ 74. (Presently Amended): A compound according to claim 1, wherein R^2 is cycloalkylalkyl.
- 73 75. (Presently Amended): A compound according to claim 72 74 wherein R¹ is alkyl, cycloalkyl or cycloalkylalkyl.
- 74. (Presently Amended): A compound according to claim 1, wherein said compound is 6-cyclopropylamino-9-(2-methoxyphenyl)-2-trifluoromethylpurine, or a pharmaceutically acceptable salt thereof.

- 75. (Presently Amended): A method according to claim <u>54</u>, <u>45</u>, wherein said compound is 6-cyclopropylamino-9-(2-methoxyphenyl)-2-trifluoromethylpurine, or a pharmaceutically acceptable salt thereof.
- 76. (New): A method according to claim 57, wherein said compound is 6-cyclopropylamino-9-(2-methoxyphenyl)-2-trifluoromethylpurine, or a pharmaceutically acceptable salt thereof.
- 77. (New): A compound according to claim 1, wherein said compound is 6-cyclopropylamino-9-(2-fluorobenzyl)-2-trifluoromethylpurine, or a pharmaceutically acceptable salt thereof
- 78. (New): A method according to claim 54, wherein said compound 6-cyclopropylamino-9-(2-fluorobenzyl)-2-trifluoromethylpurine, or a pharmaceutically acceptable salt thereof.
- 79. (New): A method according to claim 57, wherein said compound 6-cyclopropylamino-9-(2-fluorobenzyl)-2-trifluoromethylpurine, or a pharmaceutically acceptable salt thereof.
- 80. (New): A compound according to claim 1, wherein R¹ is alkyl or cycloalkyl and R² is phenyl or heteroaryl, in each case substituted or unsubstituted.
- 81. (New): A method according to claim 54, wherein R¹ is alkyl or cycloalkyl and R² is phenyl or heteroaryl, in each case substituted or unsubstituted.
- 82. (New): A method according to claim 57, wherein R¹ is alkyl or cycloalkyl and R² is phenyl or heteroaryl, in each case substituted or unsubstituted.